Sign in Subscribe
Diseases

GLP-1 Receptor Agonists: A Key to Unlocking Autoimmune Diseases Treatment

Strategic Insights

— 1 min read

A new report from Tongji University highlights the potential of glucagon-like peptide-1 (GLP-1) receptor agonists in treating autoimmune and autoinflammatory diseases. GLP-1 receptor agonists, or GLP-1RAs, have already shown effectiveness in managing type 2 diabetes mellitus and obesity. However, research suggests that these drugs may also have beneficial effects on immune cells and could potentially be used to treat a range of autoimmune conditions, including psoriasis, inflammatory bowel diseases, and multiple sclerosis.

Key Takeaways:

  • GLP-1RAs have been shown to exhibit insulinotropic effects and immunoregulation, making them a potential treatment for various autoimmune and autoinflammatory diseases.
  • The drugs have been demonstrated to have beneficial effects on immune cells through in vitro studies, preclinical models, and clinical observations.
  • Autoimmune and autoinflammatory diseases targeted by GLP-1RAs include psoriasis, inflammatory bowel diseases, rheumatoid arthritis, asthma, multiple sclerosis, Sjogren's syndrome, and systemic lupus erythematosus.
  • Tongji University researchers aim to explore the effects of GLP-1R signaling on various immune cells and evaluate the therapeutic potential of GLP-1RAs in these diseases.
  • The study highlights the potential for GLP-1RAs to become a crucial treatment option for autoimmune and autoinflammatory diseases.

Statistics:

  • 137: The article number assigned to the research paper "Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases" in the journal Cell & Bioscience.
  • 2025: The year in which the research was conducted and published.
  • 15(1): The volume and issue number of Cell & Bioscience in which the research was published.
  • People's Republic of China: The location of Tongji University, where the research was conducted.

Sources:

  • Chen, Z., et al. (2025). Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases. Cell & Bioscience, 15(1), 137.
  • Obesity & Diabetes Week (2025). New Findings on Autoimmunity from Tongji University Summarized (Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases).

Read more